07:00 - 08:00

Meet the Expert Breakfast Session

Session 7:

Newer Targets (Part 3)

Chair: David Nikolic-Paterson, Australia

08:15 - 08:35

Renal erythropoietin producing cell for anemia

Masayuki Yamamoto, Japan

08:35 - 08:55

Water channels (aquaporins)

Olivier Devuyst, Switzerland

08:55 - 09:05

Discussion

Session 8:

Advances on the evaluation for a drug nephrotoxicity

Chairs: Claudio Ronco, Italy and Masaomi Nangaku, Japan

09:05 - 09:25

Qualification of safety biomarkers

Frank D. Sistare, USA    

09:25 - 09:45

Next generation biomarkers

Joseph V. Bonventre, USA

09:45 - 09:55

Discussion

09:55 - 10:25

Coffee Break and Poster Viewing

Session 9:

Newer Targets (Part 4)

Chairs: Charles Alpers, USA and Ariela Benigni, Italy

10:25 - 10:45

MicroRNA 21 for therapeutic treatment of Alport's disease

Steve Ledbetter, USA

10:45 - 11:05

Immune cells in hypertension: perspectives from experimental data

Bernardo Rodriguez-Iturbe, Venezuela

11:05 - 11:15

Discussion

11:15 - 11:45

Keynote Lecture 4

Chair: Kai-Uwe Eckardt, Germany

Low-dose aspirin, atherothrombosis and cancer: from old trials to new
mechanistic hypotheses and new trials

Carlo Patrono, Italy

11:45 - 13:00

Potential Industry (Lunch) Symposium 3

Session 10:

Bridge of clinical data among races

Chairs: Charles Swanepoel, South Africa and Masahiro Takeuchi, Japan

13:00 - 13:20

Lessons from cohort studies

Kai-Uwe Eckardt, Germany

13:20 - 13:40

Australian Kidney Trials Network

Carmel Hawley, Australia

13:40 - 13:50

Discussion

Session 11:

Collaboration among Academia, Pharma and the Regulator (Part 2)

Chairs: Adeera Levin, Canada and Ricardo Correa-Rotter, Mexico

13:50 - 14:10

Toward better, more innovative partnership between industry and academia: messages from pharma

Kiyoshi Arita, Japan

14:10 - 14:30

Toward better, more innovative partnership between industry and academia: messages from pharma

Dennis Andress, USA

14:30 - 14:50

Approach to partnership - academia, pharma, and governmental organization: message from Australia

Vlado Perkovic, Australia

5:00 - 15:20

14:50 – 15:00

Patients, research and drugs: a view from the sharp end
Fiona Loud, UK

15:00 – 15:20

Panel Discussion

Chairs: Adeera Levin, Canada and Ricardo Correa-Rotter, Mexico

Discussants: 4 pharma

15:20 - 15:50

Coffee Break and Poster Viewing

Session 12:

Exploratory Clinical Trials (New Drugs)

Chairs: Mark Houser, USA and Albert Ong, United Kingdom

15:50 - 16:10

Novel immunosuppressive drugs and biologics

Flavio Vincenti, USA

16:10 - 16:30

Enzyme replacement therapy for Fabry's disease    

David Warnock, USA

16:30 - 16:50

In search of novel drugs for polycystic kidney and liver disease

Marie Hogan, USA

16:50 - 17:00

Discussion

Session 13:

Exploratory clinical trials (cell therapy or with innovative devices)

Chairs: Flavio Vincenti, USA and Norberto Perico, Italy

17:00 - 17:20

How to approach cell-based therapy in kidney transplantation

Ton Rabelink, The Netherlands

17:20 - 17:40

Portable and wearable dialysis

Claudio Ronco, Italy

17:40 – 18:00

Balance of Thymosin-beta 4 and AcSDKP- a Novel Target for Fibrosis 

Agnes Fogo

18:00 - 18:10

Discussion

18:10 - 19:25

Potential Industry Symposium 4